Results 11 to 20 of about 9,247 (168)
Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
Therapeutics and Clinical Risk Management, 2023 Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN ...
Hughes MS, Lentzsch S
exaly +2 more sources
Daratumumab in untreated newly diagnosed multiple myeloma
Therapeutic Advances in Hematology, 2019 The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies.
Shaji Kumar, Nadine Abdallah
exaly +2 more sources
CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
Journal of Translational Autoimmunity, 2019 Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent ...
Sonja Zweegman, Henny Otten
exaly +3 more sources
Reactions Weekly, 2020 AbstractMultiple myeloma is a proliferative disorder of plasma cells in the bone marrow with excessive monoclonal protein production. Despite the evolution of multiple drugs and management strategies including maintenance and autologous stem cell transplantation, the long-term results still remain undesirable.
Vishnu Gopal, Biswajit Dubashi
+8 more sources
Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Management of patients with refractory or frequently relapsing (r/r) immune thrombotic thrombocytopenic purpura (iTTP) remains challenging, with no established consensus on optimal therapeutic strategies.
Roman Schimmer +6 more
doaj +2 more sources
Frontiers in Oncology, 2021 Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for the treatment of this malignancy. Daratumumab exerts anti-myeloma activity by different
Massimo Offidani +6 more
doaj +1 more source
Frontiers in Oncology, 2022 BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion
Francesca Bonello +18 more
doaj +1 more source
HemaSphere, 2023 The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII receptor (CD16), but
Christie P.M. Verkleij +26 more
doaj +1 more source
Frontiers in Oncology, 2023 Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration ...
Gordon Cook +8 more
doaj +1 more source
CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
Frontiers in Immunology, 2022 RationaleRecent studies have demonstrated the feasibility of CD38-specific antibody constructs for in vivo imaging of multiple myeloma. However, detecting multiple myeloma in daratumumab-pretreated patients remains difficult due to overlapping binding ...
Luca Julius Pape +14 more
doaj +1 more source